This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and ...

The FDA published more than 200 letters that it sent to companies when it rejected their medicines, but the letters came with a caveat.

A high-stakes legal fight between Regeneron and Amgen over the blockbuster eye drug Eylea is putting the U.S. patent system ...

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

With investors and drugmakers increasingly eyeing the kidney disease space, a new company hopes to shed its underdog status ...

Next month will be the first opportunity to gauge the commercial launch of a new treatment for Prader-Willi syndrome, a rare ...

A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...

The idea of making the U.S. more like Europe is anathema to many in the Trump administration. But that’s what the Make ...

So far, benefits associated with consistent GLP-1 use in curbing medical spending lack sufficient data-backed evidence. It’s ...

The Medicare Advantage industry has aggressively sued the federal government to overturn reduced quality ratings and keep ...

Nearly 1 in 3 American adolescents have prediabetes, a CDC report finds. An official notes "it’s not too late to change ...

HHS Secretary Robert F. Kennedy Jr. has abruptly canceled a meeting of the USPSTF, an expert panel that evaluates the ...